Ulla Hedner

Ulla Hedner, MD and PhD, was Corporate Vice President, Research & Development, NovoSeven® Research, between 1989 and 2009, when she retired. She joined Novo Nordisk in 1983 as a Senior Scientist.

Following graduation from the Medical School of the University of Lund, Sweden, in 1966, she further trained in the Department of Clinical Chemistry, Blood Transfusion Centre, Department of Internal Medicine, University Hospital in Malmö, Sweden. From 1971 until 1980, she was Registrar and Associate Professor at the Department of Coagulation Disorders at the same hospital, and from 1981 until 1983 she headed the department.

She has also been Professor in Clinical Coagulation Research at the University of Gothenburg and the University of Lund and served as part-time consultant physician from 1996 to 1999 at the Department of Coagulation Disorders, Malmö University Hospital.

She conducted research at the Department of Coagulation Disorders at the same hospital between 1960 and 1983. From 1978 to 1980, she was a visiting scientist in the laboratory of Prof Earl W. Davie, Department of Biochemistry, University of Washington, Seattle, Washington.

Dr Hedner has published more than 250 publications within the field of haemostasis. She has twice addressed the prestigious Gordon Conference on Haemostasis.

In summer 2017 she published a book entitled “Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa” (Elsevier Publisher, Academic Press, AP).

Dr Hedner was elected to the Novo Nordisk Haemophilia Foundation Council in 2005 and remained in the role until end of 2021. From 2022, Dr Hedner took on an Emeritus role within the Foundation Council to ensure continuity and enable the global community of people with bleeding disorders to benefit from her expertise on an ad hoc basis.